Comparison of the efficacy of pioglitazone and metformin on ultrasound grade and liver enzymes level in patients with non-alcoholic fatty liver disease: A randomized controlled clinical trial

Abstract

Background This study aimed to evaluate the effectiveness of metformin and pioglitazone in combination with vitamin E on sonography grade and liver enzymes level in patients with non-alcoholic fatty liver disease.

Methods A randomized controlled clinical trial was designed with 68 patients diagnosed with non-alcoholic fatty liver disease by sonography and clinical examinations. Sixty-eight patients were randomly divided into two groups; 34 were assigned to receive 15 mg of pioglitazone per day and 34 were assigned to receive 1000 mg of metformin per day for 6 months. All of the patients received vitamin E at a dose of 800 IU daily for six months. The sonography grade of fatty liver and the levels of alanine aminotransferase and aspartate aminotransferase of patients were evaluated at baseline, and within three and six months after initiation of the intervention.

Results The use of metformin or pioglitazone in combination with vitamin E decreased the sonography grade of non-alcoholic fatty liver disease patients after 6 months of treatment (p-value<0.05); however, patients in metformin group benefit more compared to pioglitazone group. Patients who received metformin and vitamin E had a significant reduction in the levels of alanine aminotransferase and aspartate aminotransferase (p-value<0.05). There were no significant changes in the liver enzymes level of the patients who received pioglitazone and vitamin E (p-value>0.05).

Major conclusion The concomitant use of metformin and vitamin E significantly improves the sonography grade of fatty liver and the level of liver enzymes in patients with non-alcoholic fatty liver disease.

Key words

Non-alcoholic fatty liver disease - NAFLD - pioglitazone - metformin - ALT - AST

Publication History

Received: 17 November 2022

Accepted: 06 December 2022

Article published online:
15 February 2023

• References

• 1 Cobbina E, Akhlaghi F.. Non-alcoholic fatty liver disease (NAFLD)–pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug metabolism reviews 2017; 49: 197-211
• 2 Fazel Y, Koenig AB, Sayiner M. et al. Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism 2016; 65: 1017-1025
• 3 Burt AD, Lackner C, Tiniakos DG.. Diagnosis and Assessment of NAFLD: Definitions and Histopathological Classification. Semin Liver Dis 2015; 35: 207-220 DOI: 10.1055/s-0035-1562942.
• 4 Buzzetti E, Pinzani M, Tsochatzis EA.. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD. Metabolism 2016; 65: 1038-1048 DOI: 10.1016/j.metabol.2015.12.012.
• 5 Athyros VG, Alexandrides TK, Bilianou H. et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism 2017; 71: 17-32
• 6 Wang L, Yu S, Chan A.. Pathology of non-alcoholic fatty liver disease. Int J Dig Dis 2016; 2: 367
• 7 Rotman Y, Sanyal AJ.. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut 2017; 66: 180-190
• 8 Nseir W, Mograbi J, Ghali M.. Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies. Dig Dis Sci 2012; 57: 1773-1781 DOI: 10.1007/s10620-012-2118-3.
• 9 Sigler MA, Congdon L, Edwards KL.. An Evidence-Based Review of Statin Use in Patients With Nonalcoholic Fatty Liver Disease. Clin Med Insights Gastroenterol 2018; 11: 1179552218787502-1179552218787502 DOI: 10.1177/1179552218787502.
• 10 Viollet B, Guigas B, Sanz Garcia N. et al. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 2012; 122: 253-270 DOI: 10.1042/CS20110386.
• 11 Hajiaghamohammadi AA, Ziaee A, Oveisi S. et al. Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic Fatty liver disease: a randomized controlled pilot study. Hepat Mon 2012; 12: e6099 DOI: 10.5812/hepatmon.6099.
• 12 Brigelius-Flohé R, Kelly FJ, Salonen JT. et al. The European perspective on vitamin E: current knowledge and future research. The American Journal of Clinical Nutrition 2002; 76: 703-716 DOI: 10.1093/ajcn/76.4.703.
• 13 Leoni S, Tovoli F, Napoli L. et al. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J Gastroenterol 2018; 24: 3361-3373 DOI: 10.3748/wjg.v24.i30.3361.
• 14 Simo KA, McKillop IH, McMillan MT. et al. Does a Calculated “NAFLD Fibrosis Score” Reliably Negate the Need for Liver Biopsy in Patients Undergoing Bariatric Surgery?. Obesity Surgery 2014; 24: 15-21 DOI: 10.1007/s11695-013-1044-6.
• 15 Loomba R, Lutchman G, Kleiner DE. et al. Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2009; 29: 172-182 DOI: 10.1111/j.1365-2036.2008.03869.x.
• 16 Bugianesi E, Gentilcore E, Manini R. et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005; 100: 1082-1090 DOI: 10.1111/j.1572-0241.2005.41583.x.
• 17 Li Y, Liu L, Wang B. et al. Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Biomed Rep 2013; 1: 57-64 DOI: 10.3892/br.2012.18.
• 18 Lavine JE, Schwimmer JB, Van Natta ML. et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. Jama 2011; 305: 1659-1668 DOI: 10.1001/jama.2011.520.
• 19 Lincoff AM, Wolski K, Nicholls SJ. et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. Jama 2007; 298: 1180-1188 DOI: 10.1001/jama.298.10.1180.
• 20 Sanyal AJ, Chalasani N, Kowdley KV. et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-1685 DOI: 10.1056/NEJMoa0907929.